Metformin Induces a Dietary Restriction-like State in Human
Primary Purpose
Overweight Subjects, Metformin, Aging
Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
metformin 0.85 twice daily for 6 months
Calorie restriction
Sponsored by
About this trial
This is an interventional treatment trial for Overweight Subjects
Eligibility Criteria
Inclusion Criteria:
- Overweight
- Male
Exclusion Criteria:
- Female
- Obesity
- Using any other drugs
- < 18 years old
- > 60 years old
- Mental disorders
- Surgery history for abdomen
Sites / Locations
- Zhang JiajiaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
No Intervention
Other
Arm Label
Metformin group
Standard diet group
CR group
Arm Description
Metformin 0.85 twice daily for 6 months
Calorie restriction diet will be given to this group.
Outcomes
Primary Outcome Measures
The differences of gene expression profile among 3 groups.
The gene expression profile will be checked by microarray, and compared the number differences of pathways among 3 groups.
Secondary Outcome Measures
The differences of insulin sensitivity in 3 groups
The insulin sensitivity will be measured by insulin clamp assays, and be compared before and after 6 months as well as among 3 group at the end of this study.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02745886
Brief Title
Metformin Induces a Dietary Restriction-like State in Human
Official Title
Chronic Metformin Treatment Induces a Dietary Restriction-like State in Overweight Human
Study Type
Interventional
2. Study Status
Record Verification Date
April 2016
Overall Recruitment Status
Unknown status
Study Start Date
April 2016 (undefined)
Primary Completion Date
December 2016 (Anticipated)
Study Completion Date
December 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Xiang Guang-da
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The fact that metformin treatment has been associated with reduced risk of cancer and cardiovascular disease raises the possibility of a beneficial role of metformin for other age-related diseases. The actions of metformin resemble the effects of calorie restriction (CR) to some extent, and microarray analyses have shown that metformin induces a gene expression profile that aligns with that of CR in animal. The aim of the study is to investigate whether metformin treatment can induce dietary restriction-like state in human.
Sixty overweight subjects will be included in this study, and participants will be divided 3 groups (20 cases in each group)including metformin group (0.85, twice daily), standard diet group, and CR group. All subjects will be treated 6 months. At the end of this study, blood samples and muscle samples will be obtained.
Detailed Description
Blood samples will be obtained from all individuals. blood lipids, inflammation markers, insulin, glucose, leptin,adiponectin, ala aminotransferase, asp aminotransferase, creatine phosphokinase,lactate dehydrogenase, alkaline phosphatase,bilirubin, cyclo-oxygenase, citrate synthase, renal function, leukocyte telomere length ratio, and telomerase activity will be measured before and after the treatments.Also, hyperinsulinemic-euglycemic clamp will be performed before and after the treatments. Muscle samples will be obtained by biopsy for 9 individuals (3 cases from each group) at the end of the study. Microarray analysis will be performed for the gene expression profile from the muscle samples. Other protein expressions such asadenosine monophosphate-activated protein kinase (AMPK), peroxisome proliferator-activated receptor coactivator 1a (PGC-1a) activity,will be checked by Western blot.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight Subjects, Metformin, Aging
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Metformin group
Arm Type
Experimental
Arm Description
Metformin 0.85 twice daily for 6 months
Arm Title
Standard diet group
Arm Type
No Intervention
Arm Title
CR group
Arm Type
Other
Arm Description
Calorie restriction diet will be given to this group.
Intervention Type
Drug
Intervention Name(s)
metformin 0.85 twice daily for 6 months
Intervention Type
Behavioral
Intervention Name(s)
Calorie restriction
Primary Outcome Measure Information:
Title
The differences of gene expression profile among 3 groups.
Description
The gene expression profile will be checked by microarray, and compared the number differences of pathways among 3 groups.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
The differences of insulin sensitivity in 3 groups
Description
The insulin sensitivity will be measured by insulin clamp assays, and be compared before and after 6 months as well as among 3 group at the end of this study.
Time Frame
6 months
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Overweight
Male
Exclusion Criteria:
Female
Obesity
Using any other drugs
< 18 years old
> 60 years old
Mental disorders
Surgery history for abdomen
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Guangda Xiang, MD
Phone
13517275283
Email
Guangda64@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Guangda Xiang, MD,PhD
Phone
02750772198
Email
Guangda64@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guangda Xiang, MD,PhD
Organizational Affiliation
Wuhan General Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Zhang Jiajia
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430070
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guangda Xiang, MD, PhD
Phone
02750772981
Email
Guangda64@hotmail.com
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Metformin Induces a Dietary Restriction-like State in Human
We'll reach out to this number within 24 hrs